AstraZeneca says detained China head has lawyer

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Justin Smith has given his Buy rating due to a combination of factors that highlight AstraZeneca’s potential amidst current challenges. Despite concerns surrounding an investigation in China, ...
Trump has threatened to slap a tariff of up to 60% on all goods imported to the U.S. from China. But Soriot called his ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl ...